IDEXX Laboratories (IDXX) Competitors $420.91 -2.74 (-0.65%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IDXX vs. IMMU, LNTH, NEOG, QDEL, CLDX, BSX, MDT, BDX, EW, and RMDShould you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Immunomedics (IMMU), Lantheus (LNTH), Neogen (NEOG), QuidelOrtho (QDEL), Celldex Therapeutics (CLDX), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and ResMed (RMD). These companies are all part of the "medical" sector. IDEXX Laboratories vs. Immunomedics Lantheus Neogen QuidelOrtho Celldex Therapeutics Boston Scientific Medtronic Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories (NASDAQ:IDXX) and Immunomedics (NASDAQ:IMMU) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Which has stronger valuation & earnings, IDXX or IMMU? IDEXX Laboratories has higher revenue and earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEXX Laboratories$3.66B9.42$845.04M$10.3740.59Immunomedics$290K70,028.66-$357.19M-$1.84-47.75 Do insiders & institutionals have more ownership in IDXX or IMMU? 87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 88.9% of Immunomedics shares are held by institutional investors. 2.1% of IDEXX Laboratories shares are held by company insiders. Comparatively, 12.0% of Immunomedics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is IDXX or IMMU more profitable? IDEXX Laboratories has a net margin of 22.53% compared to Immunomedics' net margin of 0.00%. IDEXX Laboratories' return on equity of 55.42% beat Immunomedics' return on equity.Company Net Margins Return on Equity Return on Assets IDEXX Laboratories22.53% 55.42% 25.90% Immunomedics N/A -132.40%-51.32% Do analysts rate IDXX or IMMU? IDEXX Laboratories currently has a consensus price target of $552.38, indicating a potential upside of 31.23%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Immunomedics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEXX Laboratories 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Immunomedics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in IDXX or IMMU? IDEXX Laboratories received 90 more outperform votes than Immunomedics when rated by MarketBeat users. Likewise, 72.24% of users gave IDEXX Laboratories an outperform vote while only 65.24% of users gave Immunomedics an outperform vote. CompanyUnderperformOutperformIDEXX LaboratoriesOutperform Votes53172.24% Underperform Votes20427.76% ImmunomedicsOutperform Votes44165.24% Underperform Votes23534.76% Which has more volatility and risk, IDXX or IMMU? IDEXX Laboratories has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Immunomedics has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500. Does the media prefer IDXX or IMMU? In the previous week, IDEXX Laboratories had 21 more articles in the media than Immunomedics. MarketBeat recorded 21 mentions for IDEXX Laboratories and 0 mentions for Immunomedics. IDEXX Laboratories' average media sentiment score of 1.27 beat Immunomedics' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Overall Sentiment IDEXX Laboratories Positive Immunomedics Neutral SummaryIDEXX Laboratories beats Immunomedics on 14 of the 18 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get IDEXX Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXX vs. The Competition Export to ExcelMetricIDEXX LaboratoriesDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.47B$2.19B$5.12B$8.72BDividend YieldN/A0.72%5.18%4.07%P/E Ratio40.592.4372.8114.16Price / Sales9.4239.681,250.2081.71Price / Cash36.4214.7440.7036.03Price / Book21.302.996.455.94Net Income$845.04M$29.98M$119.73M$225.73M7 Day Performance-2.85%-11.24%-5.13%-1.34%1 Month Performance-8.50%-12.49%-2.71%1.15%1 Year Performance-9.23%-20.97%31.08%24.02% IDEXX Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXXIDEXX Laboratories4.878 of 5 stars$420.91-0.6%$552.38+31.2%-9.8%$34.47B$3.66B40.5911,000Options VolumePositive NewsIMMUImmunomedicsN/A$87.86flatN/AN/A$20.31B$290,000.00-50.79366LNTHLantheus4.6074 of 5 stars$76.83-5.0%N/A+12.7%$5.34B$1.30B12.78834NEOGNeogen2.224 of 5 stars$14.60-0.3%N/A-8.5%$3.16B$912.20M-132.732,640QDELQuidelOrtho4.437 of 5 stars$36.18-7.1%N/A-44.8%$2.43B$2.82B-1.307,100Options VolumeCLDXCelldex Therapeutics2.7989 of 5 stars$23.55-8.5%N/A-15.3%$1.56B$9.98M-9.16160Insider BuyingBSXBoston Scientific4.6224 of 5 stars$86.99-0.7%N/A+59.1%$128.21B$14.24B71.8948,000Short Interest ↑News CoverageMDTMedtronic4.8643 of 5 stars$87.53+1.8%N/A+16.9%$112.25B$32.58B29.5795,000Upcoming EarningsAnalyst ForecastNews CoverageBDXBecton, Dickinson and Company4.9898 of 5 stars$225.15-0.9%N/A-4.2%$65.08B$20.18B37.9073,000Short Interest ↓News CoveragePositive NewsEWEdwards Lifesciences4.55 of 5 stars$67.76+2.4%N/A+0.4%$39.96B$6.00B9.7819,800Insider SellingShort Interest ↓Analyst RevisionRMDResMed4.7246 of 5 stars$234.74+1.4%N/A+57.6%$34.46B$4.81B31.099,980Insider SellingAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies IMMU Alternatives LNTH Alternatives NEOG Alternatives QDEL Alternatives CLDX Alternatives BSX Alternatives MDT Alternatives BDX Alternatives EW Alternatives RMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDXX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEXX Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
